2016 – Page 3 – Biotechblog

Formulary Best Practice: Cost Containment through Generic Drugs

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below. […]

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below.

This is a guest post from Rajan Pragani, an FDA scientist, as part of his final project the the NIH’s

The latest issue of the Journal of Commercial Biotechnology is now available. Check out the Table of Contents below, and

This is a guest post from Brannon Cashion, President of Addison Whitney Health. Do you have a response to Brannin’s post?

Following two posts on Brexit and British biotechnology, I would like to provide a perspective that turns everything on its

In the wake of my recent post on the potential impact of Brexit on British Biotechnology, I am fortunate to

I have a tool that can be used to measure the impact of Brexit on biotechnology in the United Kingdom.

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s

DrugPatentWatch offers PDF copies of the FDA Orange Book dating back to 1980. The Food and Administration (FDA) Orange Book, or Approved